RU95114405A - USE OF RILUZOL AS A MEDICINAL PRODUCT FOR TREATMENT OF NEUROLOGICAL DISORDERS CAUSED BY INJURIES AND METHOD FOR PRODUCING A MEDICINE - Google Patents

USE OF RILUZOL AS A MEDICINAL PRODUCT FOR TREATMENT OF NEUROLOGICAL DISORDERS CAUSED BY INJURIES AND METHOD FOR PRODUCING A MEDICINE

Info

Publication number
RU95114405A
RU95114405A RU95114405/14A RU95114405A RU95114405A RU 95114405 A RU95114405 A RU 95114405A RU 95114405/14 A RU95114405/14 A RU 95114405/14A RU 95114405 A RU95114405 A RU 95114405A RU 95114405 A RU95114405 A RU 95114405A
Authority
RU
Russia
Prior art keywords
injuries
neurological disorders
treatment
disorders caused
medicine
Prior art date
Application number
RU95114405/14A
Other languages
Russian (ru)
Other versions
RU2142800C1 (en
Inventor
Добл Эдам
Лувель Эрик
Прэт Джереми
Стютзманн Жан-Мари
Original Assignee
Рон-Пуленк Роре С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9215148A external-priority patent/FR2699077B1/en
Application filed by Рон-Пуленк Роре С.А. filed Critical Рон-Пуленк Роре С.А.
Publication of RU95114405A publication Critical patent/RU95114405A/en
Application granted granted Critical
Publication of RU2142800C1 publication Critical patent/RU2142800C1/en

Links

Claims (7)

1. Применение рилузола или фармацевтически пригодных солей этого соединения в качестве лекарственного средства, предназначенного для лечения неврологических нарушений, вызванных травмами.1. The use of riluzole or pharmaceutically acceptable salts of this compound as a medicine for the treatment of neurological disorders caused by injuries. 2. Применение по п. 1, в качестве лекарственного средства, предназначенного для лечения неврологических нарушений, вызванных спинно-мозговыми травмами. 2. The use according to claim 1, as a medicine intended for the treatment of neurological disorders caused by spinal cord injuries. 3. Применение по п. 1, в качестве лекарственного средства, предназначенного для лечения неврологических нарушений, вызванных черепными травмами. 3. The use according to claim 1, as a medicine intended for the treatment of neurological disorders caused by cranial injuries. 4. Применение по п. 1, в качестве лекарственного средства, предназначенного для лечения неврологических нарушений, вызванных черепно-спинальными травмами. 4. The use according to claim 1, as a medicine intended for the treatment of neurological disorders caused by cranio-spinal injuries. 5. Применение по любому из пп. 1-4, в котором лекарственное средство, вводимое оральным путем, содержит 25-200 мг рилузола. 5. The use according to any one of paragraphs. 1-4, in which the drug is administered orally, contains 25-200 mg of riluzole. 6. Применение по любому из пп. 1-4, в котором лекарственное средство, вводимое внутривенно, содержит 12,5-200 мг рилузола. 6. The use according to any one of paragraphs. 1-4, in which the drug is administered intravenously, contains 12.5-200 mg of riluzole. 7. Способ получения лекарственного средства, используемого для лечения неврологических нарушений, вызванных травмами, а в частности спинно-мозговыми травмами, черепными травмами или черепно-спинальными травмами, отличающийся тем, что смешивают рилузол или фармацевтически пригодные соли этого соединения с одним или несколькими разбавителями и/или совместимыми и фармацевтически пригодными добавками. 7. A method of obtaining a medicinal product used to treat neurological disorders caused by injuries, and in particular spinal cord injuries, cranial injuries or cranio-spinal injuries, characterized in that riluzole or pharmaceutically acceptable salts of this compound are mixed with one or more diluents and / or compatible and pharmaceutically acceptable additives.
RU95114405A 1992-12-16 1993-12-10 Use of rilusol as drug for treatment of patients with neurological disorders caused by traumas and method of drug preparing RU2142800C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9215148A FR2699077B1 (en) 1992-12-16 1992-12-16 Application of anticonvulsants in the treatment of neurological lesions linked to trauma.
FR9215148 1992-12-16
PCT/FR1993/001229 WO1994013288A1 (en) 1992-12-16 1993-12-10 Application of riluzole in the treatment of neurological lesions related to traumatic injuries

Publications (2)

Publication Number Publication Date
RU95114405A true RU95114405A (en) 1997-07-27
RU2142800C1 RU2142800C1 (en) 1999-12-20

Family

ID=9436652

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95114405A RU2142800C1 (en) 1992-12-16 1993-12-10 Use of rilusol as drug for treatment of patients with neurological disorders caused by traumas and method of drug preparing

Country Status (23)

Country Link
US (1) US5830907A (en)
EP (3) EP0674520A1 (en)
JP (3) JPH08504429A (en)
KR (3) KR950703968A (en)
AT (1) ATE164067T1 (en)
AU (3) AU5653994A (en)
CA (3) CA2151603A1 (en)
CZ (3) CZ284420B6 (en)
DE (1) DE69317578T2 (en)
DK (1) DK0674512T3 (en)
ES (1) ES2113635T3 (en)
FR (1) FR2699077B1 (en)
GR (1) GR3026403T3 (en)
HU (3) HUT71812A (en)
IL (3) IL108053A0 (en)
MX (3) MX9307883A (en)
NO (3) NO307027B1 (en)
PL (3) PL309347A1 (en)
RU (1) RU2142800C1 (en)
SK (3) SK78795A3 (en)
UA (1) UA41906C2 (en)
WO (3) WO1994013288A1 (en)
ZA (3) ZA939401B (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (en) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application of anti-convulsants in the treatment of Parkinson's disease and parkinsonian syndromes.
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
FR2733684B1 (en) 1995-05-03 1997-05-30 Cird Galderma USE OF RETINOIDS IN A COSMETIC COMPOSITION OR FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
CO4920215A1 (en) * 1997-02-14 2000-05-29 Novartis Ag OXACARBAZEPINE TABLETS COATED WITH A FILM AND METHOD FOR THE PRODUCTION OF THESE FORMULATIONS
AU744997B2 (en) * 1997-09-05 2002-03-07 Glaxo Group Limited 2,3-diaryl-pyrazolo(1,5-B)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
GB9808015D0 (en) * 1998-04-15 1998-06-17 United Medical And Dental Scho Protection of the nervous system from the effects of inflammatory disease
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
FR2787028B1 (en) * 1998-12-15 2002-10-18 Aventis Pharma Sa USE OF RILUZOLE IN THE TREATMENT OF ACOUSTIC TRAUMA
US6239156B1 (en) * 1999-04-29 2001-05-29 Centre National De La Recherche Scientifique Cnrs Method for the prevention of ischemic spinal cord injury caused by aortic crossclamping
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
US9629817B2 (en) 2005-08-25 2017-04-25 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
CA2872975A1 (en) * 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
EP2847158A4 (en) 2012-05-07 2015-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
JP2015518855A (en) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of mucositis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
JP2015518854A (en) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of multiple sclerosis
JP6202287B2 (en) 2012-05-23 2017-09-27 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of inflammatory bowel disease
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3242869B1 (en) 2015-01-06 2021-10-27 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and pain
ES2930848T3 (en) 2015-09-23 2022-12-22 Xwpharma Ltd Gamma-hydroxybutyric acid prodrugs, compositions and uses thereof
AU2017406159B2 (en) 2017-03-30 2020-05-21 XWPharma Ltd. Bicyclic heteroaryl derivatives and preparation and uses thereof
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
US20200289476A1 (en) * 2017-11-28 2020-09-17 University Of Houston System Liquid formulations of riluzole for oral and intravenous use
EP3856719B1 (en) 2018-09-30 2023-06-07 XWPharma Ltd. Compounds as neuronal histamine receptor-3 antagonists and uses thereof
CN115244028A (en) 2019-12-20 2022-10-25 凯瑞康宁生物工程有限公司 Synthetic method of 4-valyloxy butyric acid
KR20230008190A (en) 2020-06-18 2023-01-13 엑스더블유파마 리미티드 Pharmaceutical granulating agent for water-soluble drug substances
CA3182394A1 (en) 2020-06-18 2021-12-23 Sami Karaborni Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
JP2023544420A (en) 2020-10-05 2023-10-23 エックスダブリューファーマ リミテッド Modified release compositions of gamma-hydroxybutyric acid derivatives
JP2024511991A (en) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド Pharmacokinetics of combined release formulations of gamma-hydroxybutyric acid derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK153787C (en) * 1979-06-01 1989-01-16 Wellcome Found METHOD OF ANALOGUE FOR THE PREPARATION OF SUBSTITUTED 3,5-DIAMINO-6-PHENYL-1,2,4-TRIAZINES AND ALFA-CYANOBENZYLIDEEN-AMINOGUANIDE COMPOUNDS FOR USE AS INTERMEDIATES
FR2492258A1 (en) * 1980-10-17 1982-04-23 Pharmindustrie NEW AMINO-2 TRIFLUOROMETHOXY-6 BENZOTHIAZOLE-BASED MEDICINAL PRODUCT
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US4918090A (en) * 1988-01-25 1990-04-17 Warner-Lambert Company Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
US5240948A (en) * 1989-12-13 1993-08-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. 3-(3-alkylthiopropyl)benzothiazoline derivatives, their preparation and the medicament containing them
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
JPH06506455A (en) * 1991-02-08 1994-07-21 ケンブリッジ・ニューロサイエンス・インコーポレイテッド Novel method for identifying guanidine substitutes and their derivatives as neurotransmitter release modulators and neurotransmitter release blockers
FR2688138B1 (en) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa APPLICATION OF AMINO-2 TRIFLUOROMETHOXY-6 BENZOTHIAZOLE TO OBTAIN A MEDICINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.

Similar Documents

Publication Publication Date Title
RU95114405A (en) USE OF RILUZOL AS A MEDICINAL PRODUCT FOR TREATMENT OF NEUROLOGICAL DISORDERS CAUSED BY INJURIES AND METHOD FOR PRODUCING A MEDICINE
Pei A review of pharmacology and clinical use of piperine and its derivatives
RU95121731A (en) APPLICATION OF RILUZOL FOR THE TREATMENT OF NEURO AIDS AND THE METHOD FOR PRODUCING A MEDICINE
KR950703968A (en) APPLICATION OF CARBAMAZEPINE AND OXCARBAZEPINE IN THE TREATMENT OF NEUROLOGICAL LESIONS RELATED TO TRAUMATIC INJURIES
DE69805202T2 (en) USE OF BENZHYDRYLSULFINYL DERIVATIVES FOR TREATING THE SLEEPNESS DRUG-ORIGINAL ORIGIN
HUP0203325A2 (en) Bicyclic amino acids, pharmaceutical compositions containing them and their use
CA2179521A1 (en) 2,4-disulphophenyl butylnitrone, its salts and their use as pharmaceuti cal spintraps
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
ES2173111T3 (en) USE OF FENSERINE FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF COGNOSCITIVE DISORDERS.
KR960700716A (en) USE OF RILUZOLE FOR TREATING AIDS-RELATED NEURAL DISORDERS
CY1105507T1 (en) SUBSTITUTED PYRAZOLE- AND THIAZOLOPYRIMIDINES
DE69521536D1 (en) Compositions containing G-CSF and a TNF binding protein
TW197423B (en)
HUT62192A (en) Process for producing pharmaceutical compositions comprising tomoxetine and suitable for treating diseases of lower urinary tract
ES2356617T3 (en) CARBAMATE COMPOUNDS FOR USE IN PAIN TREATMENT.
RU97104483A (en) SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT
RU2152215C1 (en) Use of ropivacaine in preparing pharmaceutical preparation with analgetic effect and minimal motor blockade
IL90418A0 (en) Condensed diazepinones,their preparation and pharmaceutical compositions containing them
US3903301A (en) Methods of treating muscular disorders
RU95114403A (en) APPLICATION OF LAMOTRIGIN AS A MEDICINE FOR TREATMENT OF NEUROLOGICAL DISORDERS CAUSED BY INJURIES AND METHOD OF OBTAINING A MEDICINE
IT1276462B1 (en) ACID AROMATIC DIAMIDES WITH ANTIGASTRINIC ACTIVITY, PROCEDURE FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE
DE345883T1 (en) USE OF DAPIPRAZOLE FOR PRODUCING A MEDICINAL PRODUCT TO PREVENT TOLERANCE DEVELOPMENT IN ANALGETIC TREATMENT WITH MORPHINE.
RU97104062A (en) APPLICATION OF SELEGYLIN FOR TREATMENT OF EPILEPTIC DISEASES
US5081129A (en) Method of treatment of anemia with seratonin antagonists
RU95115404A (en) APPLICATION OF RILUZOLE AS A MEANS FOR THE TREATMENT OF PARKINSON'S DISEASE AND PARKINSON'S SYNDROMES, METHOD FOR PRODUCING A MEDICINE